USPTO 2015–2025 USPTO PatentsView Foreign Corporation

ResMed Pty Ltd

USPTO PatentsView assignee record — 800 granted patents across 62 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).

800
Total patents granted
62
CPC technology areas
22.5
Avg claims per patent
+1133%
5-year filing velocity

Portfolio overview

ResMed Pty Ltd has been granted 800 US utility patents between 2019 and 2025, placing ResMed Pty Ltd at rank #565 across all assignees tracked by PlainPatent. This portfolio spans 62 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.5 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a Foreign Corporation, ResMed Pty Ltd is one of the broader-portfolio assignees in the PatentsView dataset. The composite Innovation Score of 70.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 740 grants, compared with 60 in the 2015–2019 window — a +1133% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. ResMed Pty Ltd's 22.5 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while a multi-domain presence across 62 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark ResMed Pty Ltd against peers pursuing similar technology classes.

How does ResMed compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows ResMed holds 800 patents — placing it at rank #565 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2019–2025

50100150200 2019202020212022202320242025 84
USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table
ResMed Pty Ltd patent grants by year, 2015–2025
Year Patents Granted Share of Period
2019 60 7.5%
2020 131 16.4%
2021 122 15.3%
2022 161 20.1%
2023 130 16.3%
2024 112 14.0%
2025 84 10.5%

Which technologies does ResMed Pty Ltd patent most?

Top 15 of 62 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Complex
Velocity Accelerating

Where it ranks

Overall rank by patents

#565

Across all tracked assignees

Innovation Score

70.2 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does ResMed Pty Ltd hold?
ResMed Pty Ltd holds 800 US granted patents filed between 2019 and 2025, spanning 62 technology areas.
What is ResMed Pty Ltd's Innovation Score?
ResMed Pty Ltd has an Innovation Score of 70.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does ResMed Pty Ltd focus on?
ResMed Pty Ltd's top technology area is A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR) with 682 patents. The company has filed patents in 62 CPC subclasses total.
Is ResMed Pty Ltd's patent filing rate increasing or decreasing?
ResMed Pty Ltd's recent filing velocity is +1133% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for ResMed Pty Ltd's patents?
ResMed Pty Ltd's patents average 22.5 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the ResMed Pty Ltd patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope